Genitourinary Cancers Symposium Annual Meeting Coverage

Support for Adjuvant Chemotherapy in Nonmetastatic Bladder Cancer

Support for Adjuvant Chemotherapy in Nonmetastatic Bladder Cancer

Adjuvant chemotherapy is associated with better survival among patients with advanced nonmetastatic bladder cancer.

Low-dose Brachytherapy Provides Better Outcomes in Intermediate PCa

Low-dose Brachytherapy Provides Better Outcomes in Intermediate PCa

Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.

Short-Term ADT+Radiotherapy Does Not Help Intermediate PCa Survival

Short-Term ADT+Radiotherapy Does Not Help Intermediate PCa Survival

Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.

Early Bicalutamide Aids Survival in Nonmetastatic Prostate Cancer

Early Bicalutamide Aids Survival in Nonmetastatic Prostate Cancer

Adding bicalutamide improves overall survival among patients with advanced nonmetastatic hormone-naïve prostate cancer.

Prostate Cancer Active Surveillance Outcomes Vary by Disease Risk

Prostate Cancer Active Surveillance Outcomes Vary by Disease Risk

Cancer-specific and overall survival is decreased in men with intermediate-risk versus low-risk tumors.

High BMI a Plus for Some Metastatic Kidney Cancer Patients

High BMI a Plus for Some Metastatic Kidney Cancer Patients

Overweight or obese patients treated with targeted therapy for metastatic clear-cell renal cell carcinoma found to live longer.

Statins May Prolong Life in Patients with Advanced Kidney Cancer

Statins May Prolong Life in Patients with Advanced Kidney Cancer

In a study of 4,736 patients with metastatic renal cell carcinoma, use of the drugs was associated with a nearly 22% decreased risk of death.

Adjuvant Kidney Cancer Drugs Fail to Improve Outcomes

Adjuvant Kidney Cancer Drugs Fail to Improve Outcomes

Sorafenib or sunitinib given after surgery for advanced renal cell carcinoma does not improve progression-free survival, study shows.

Statins Plus ADT After Prostate Cancer Radiotherapy Ups Survival

Statins Plus ADT After Prostate Cancer Radiotherapy Ups Survival

Researchers observed a significant 36% decreased overall and prostate cancer-specific mortality.

Identifying Urothelial Cancer Subtypes Matters

Identifying Urothelial Cancer Subtypes Matters

It has implications for treatment decisions and prognosis.

BCG + Sunitinib Promising for High-Risk Bladder Cancer

BCG + Sunitinib Promising for High-Risk Bladder Cancer

In a phase 2 trial, 72% of patients with high-grade clinical nonmuscle-invasive bladder cancer had a complete response at 3 months.

New Tool Could Spare Men Unnecessary Prostate Biopsies

New Tool Could Spare Men Unnecessary Prostate Biopsies

The 4Kscore enables better identification of men who harbor high-grade prostate cancer.

Radiation Plus ADT Beneficial in Node-Positive Prostate Cancer

Radiation Plus ADT Beneficial in Node-Positive Prostate Cancer

The 5-year risk of overall mortality is decreased by 50% compared with androgen deprivation therapy alone.

Better mCRPC Survival with Docetaxel Followed by Abiraterone

Better mCRPC Survival with Docetaxel Followed by Abiraterone

This medication sequence was associated with longer progression-free and overall survival compared with the reverse.

Genitourinary Cancer in Siblings Raises Personal Risk

Genitourinary Cancer in Siblings Raises Personal Risk

Researchers found elevated familial risks for testicular, prostate, bladder, and kidney cancers.

Sign Up for Free e-newsletters